Glaucoma has no early symptoms — it quietly damages your optic nerve until you notice vision loss. That's why treatment is lifelong. The UK ophthalmic drugs market research shows that antiglaucoma drugs are the fastest‑growing segment, with a CAGR above 6%. Why? Because the UK has an aging population, and screening programmes are catching more cases early.

What's in the pipeline? Prostaglandin analogs (latanoprost, bimatoprost) are first‑line — they work well and have few side effects. Newer drugs like netarsudil (Rhopressa) target the trabecular meshwork, lowering pressure through a different mechanism. The UK ophthalmic drugs market trends highlight that the fastest‑growing route of administration is intravitreal, but for glaucoma, topical (eye drops) still dominates.

But compliance is a problem. Many patients forget to take their drops, or can't afford them. That's why sustained‑release implants (Bimatoprost SR) are in development — one implant lasts months.

The bottom line: if you have glaucoma, take your drops every day. Skipping doses lets pressure rise, causing irreversible damage.